Target intelligence / Profile preview

Zika virus envelope glycoprotein quaternary dimer-dimer interface epitope (ZIKV E dimer-dimer epitope)

Target
ZIKV E dimer-dimer epitope
Molecular classification
Viral surface protein, Glycoprotein, Quaternary epitope, Flavivirus envelope protein
01

Overview

The Zika virus envelope (E) glycoprotein is the primary protein on the viral surface, organized into 90 homodimers that form a herringbone pattern (Sankhala et al., 2023). The quaternary epitope at the dimer-dimer interface is a complex antigenic site formed by the juxtaposition of two adjacent E protein dimers on the mature virion (Sapparapu et al., 2016). This epitope is a critical target for potently neutralizing human monoclonal antibodies, such as ZIKV-117, which bind across the interface to lock the dimers in place (Zhang et al., 2016). By stabilizing the dimeric structure, these antibodies prevent the large-scale conformational changes—specifically the transition from dimers to fusogenic trimers—required for membrane fusion and viral entry into host cells (Long et al., 2020). Targeting this specific quaternary structure is a key strategy in developing ZIKV-specific therapeutics and vaccines that aim to provide high potency while minimizing the risk of antibody-dependent enhancement (ADE) associated with cross-reactive antibodies to other flaviviruses like Dengue (Sankhala et al., 2023).

Other names
Zika virus envelope protein inter-dimer epitopeZIKV E quaternary epitopeZIKV E-raft epitopeZika virus envelope glycoprotein dimer-dimer interface
02

Mechanism of action

Neutralization of viral infection by binding across adjacent envelope protein dimers to stabilize the mature virion structure and inhibit the dimer-to-trimer transition required for membrane fusion.

03

Biological functions

Viral attachmentViral entryMembrane fusionViral assembly
04

Disease associations

InfectionZika virus infectionCongenital Zika syndromeGuillain-Barré syndrome
05

Safety considerations

Antibody-dependent enhancement (ADE) of infectionCross-reactivity with Dengue virusViral escape mutations
06

Interacting drugs

ZIKV-117

5 more in the full profile.

07

Biomarkers

Zika virus RNA (viremia)Zika virus-specific IgMZika virus-specific IgGPlaque Reduction Neutralization Test (PRNT) titers

Beyond the preview

Go deeper on Zika virus envelope glycoprotein quaternary dimer-dimer interface epitope (ZIKV E dimer-dimer epitope).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zika virus envelope glycoprotein quaternary dimer-dimer interface epitope (ZIKV E dimer-dimer epitope).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call